1. Kontermann, R. E. (2005) Recombinant bispecific antibodies for cancer therapy. Acta. Pharmacol. Sin.
26, 1–9.
2. Kipriyanov, S. M. and Le Gall F. (2004) Recent advances in the generation of bispecific antibodies for tumor immunotherapy. Curr. Opin. Drug Discov. Devel.
7, 233–242.
3. Lum, L. G., and Davol, P. A. (2005) Retargeting T cells and immune effector cells with bispecific antibodies. Cancer Chemother. Biol. Response Modif.
22, 273–291.
4. Marvin, J. S., and Zhu, Z. (2006) Bispecific antibodies for dual-modality cancer therapy: killing two signaling cascades with one stone. Curr. Opin. Drug Discov. Devel.
9, 184–193.
5. Lu, D., Zhang, H., Koo, H., Tonra, J., Balderes, P., Prewett, M., Corcoran, E., Mangalampalli. V/, Bassi. R., Anselma, D., Patel, D., Kang, X., Ludwig, D. L., Hicklin, D. J., Bohlen, P., Witte, L., and Zhu, Z. (2005) A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J. Biol. Chem.
280, 19665–19672.